MSN Group rolls out anti-epileptic drug for infants

Hyderabad: City-based leading pharmaceutical company MSN Labs has launched anti-epileptic and India's first generic Vigabatrin powder for oral solution under the brand name Viganext.

Vigabatrin is recommended as the first-line therapy for Infantile Spasm, a form of epilepsy that affects 1 in 2,000 children. Previously, the availability of the drug was wholly dependent on grey market imports which were severely disrupted during the Covid-19 lockdowns impacting thousands of patients.

Appreciating the scarcity of the medicine, MSN Labs reached out to Drugs Controller General of India (DCGI) for necessary approval to serve epilepsy patients in India with an uninterrupted supply of affordable Vigabatrin.

MSN group said that besides being a remarkable addition to our ever-expanding product basket, this drug benefits the patients in India by expanding the choice of affordable therapeutic options available to them.